<p>/PRNewswire/ - Kent Imaging 今天就 MolecuLight Corp. 和 MolecuLight Inc. 在美国国际贸易委员会 (ITC) 提起的投诉发表声明。该投诉指控 Kent Imaging 的 SnapshotGLO®，该产品最近获得 FDA 510(k) 许可，侵犯了 MolecuLight 声称拥有许可的专利。Kent Imaging 否认投诉中所有的专利侵权指控，并对 MolecuLight 的主张毫无依据充满信心。Kent Imaging 在创新方面的良好记录强调了其对他人知识产权的高度尊重，并打算全力以赴、毫不妥协地捍卫自己，反对 MolecuLight 的无端指控。</p>
<p>&#34;Kent 的 Snapshot 产品线，包括 SnapshotGLO，反映了多年的严谨研究、专利创新以及对临床需求的坚定关注，&#34; Kent Imaging 首席执行官 Pierre Lemire 说。&#34;我们对我们的知识产权充满信心，坚定我们的立场，并致力于确保临床医生继续不间断地获得能够实质改善患者结果的技术。&#34;</p>
<p>随着 SnapshotGLO 的推出，Kent Imaging 的旗舰产品 SnapshotNIR® 也在推进诊断成像，采用互补的双模态方法。这些技术共同提升了先进伤口护理的科学性和临床影响，使得早期干预和治疗决策的精准度得以提高。</p>
<p>Kent Imaging 继续经历强劲增长，投资于持续的研究和开发，目标是提供关键工具，帮助临床医生为患者实现更好的健康结果。</p>
<p><strong>关于 Kent Imaging</strong></p>
<p>Kent Imaging 总部位于加拿大阿尔伯塔省卡尔加里，是先进诊断成像技术的领先创新者。该公司设计、制造和销售支持伤口护理、血管和外科专业实时决策的医疗设备。通过专利技术，Kent 不断提供突破性解决方案，支持全球医疗系统。</p>
<p>Snapshot 产品系列现在包括两款强大的成像设备：SnapshotNIR，一种近红外组织氧合成像设备，最初于 2017 年获得 FDA 和加拿大卫生部的批准，并于 2025 年获得 CE 认证；以及 SnapshotGLO，一种细菌自发荧光成像设备，于 2025 年获得 FDA 510(k) 许可。SnapshotNIR 得到了临床证据的支持，证明其在增强临床决策中的作用，而 SnapshotGLO 则提供了对伤口生物负荷存在和分布的实时洞察。这些 Snapshot 产品系列共同增强了临床医生的检测、指导和保护能力，促进了治疗的一致性，支持了改善工作流程，并为全球更好的患者护理做出了贡献。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SnapshotGLO® 是 Kent Imaging Inc. 的注册商标。</td>
</tr>
<tr>
<td></td>
<td>SnapshotNIR® 是 Kent Imaging Inc. 的注册商标。</td>
</tr>
</tbody>
</table>
<p>来源 Kent Imaging</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE5Jk5ld3NJdGVtSWQ9Q0E2NTM3NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTkwODAwUFJfTkVXU19VU1BSX19fX19DQTY1Mzc2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE5Jk5ld3NJdGVtSWQ9Q0E2NTM3NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTkwODAwUFJfTkVXU19VU1BSX19fX19DQTY1Mzc2"/></p>

<p>Kent Imaging 对 MolecuLight Corp. 向美国国际贸易委员会提出的关于其 SnapshotGLO® 设备的专利侵权投诉作出了回应。Kent Imaging 否认这些指控，并对其知识产权充满信心。该公司强调其对临床创新的承诺，以及其 Snapshot 产品线在改善患者结果方面的重要性。Kent Imaging 继续投资于研发，以提升伤口护理和其他医疗专业的诊断成像技术</p>

<p>, /PRNewswire/ - Kent Imaging today issued a statement regarding the complaint filed by MolecuLight Corp. and MolecuLight Inc. in the U.S. International Trade Commission (ITC). The complaint alleges that Kent Imaging's SnapshotGLO®, which recently received FDA 510(k) clearance, infringes a patent to which MolecuLight purports to have a license. Kent Imaging denies all allegations of patent infringement in the complaint and is confident that MolecuLight's claims are without merit. Underscored by its track record for innovation, Kent Imaging maintains the highest respect for the intellectual property rights of others and intends to defend itself fully and fiercely against MolecuLight's unfounded claims.</p>
<div class="lb-trans"><p>/PRNewswire/ - Kent Imaging 今天就 MolecuLight Corp. 和 MolecuLight Inc. 在美国国际贸易委员会 (ITC) 提起的投诉发表声明。该投诉指控 Kent Imaging 的 SnapshotGLO®，该产品最近获得 FDA 510(k) 许可，侵犯了 MolecuLight 声称拥有许可的专利。Kent Imaging 否认投诉中所有的专利侵权指控，并对 MolecuLight 的主张毫无依据充满信心。Kent Imaging 在创新方面的良好记录强调了其对他人知识产权的高度尊重，并打算全力以赴、毫不妥协地捍卫自己，反对 MolecuLight 的无端指控。</p>
</div><p>&#34;Kent's Snapshot product line, including SnapshotGLO, reflects years of disciplined research, patented innovation, and an unwavering focus on clinician needs,&#34; said Pierre Lemire, CEO, Kent Imaging. &#34;We are confident in our intellectual property, resolute in our position, and committed to ensuring clinicians continue to have uninterrupted access to technologies that materially improve patient outcomes.&#34;</p>
<div class="lb-trans"><p>&#34;Kent 的 Snapshot 产品线，包括 SnapshotGLO，反映了多年的严谨研究、专利创新以及对临床需求的坚定关注，&#34; Kent Imaging 首席执行官 Pierre Lemire 说。&#34;我们对我们的知识产权充满信心，坚定我们的立场，并致力于确保临床医生继续不间断地获得能够实质改善患者结果的技术。&#34;</p>
</div><p>With the introduction of SnapshotGLO alongside Kent Imaging's flagship product, SnapshotNIR®, Kent is advancing diagnostic imaging through a complementary, dual-modality approach. Together, these technologies elevate both the science and clinical impact of advanced wound care, enabling earlier intervention and greater precision in treatment decisions.</p>
<div class="lb-trans"><p>随着 SnapshotGLO 的推出，Kent Imaging 的旗舰产品 SnapshotNIR® 也在推进诊断成像，采用互补的双模态方法。这些技术共同提升了先进伤口护理的科学性和临床影响，使得早期干预和治疗决策的精准度得以提高。</p>
</div><p>Kent Imaging continues to experience strong growth as it invests in ongoing research and development with the goal of delivering critical tools that help clinicians achieve better health outcomes for their patients.</p>
<div class="lb-trans"><p>Kent Imaging 继续经历强劲增长，投资于持续的研究和开发，目标是提供关键工具，帮助临床医生为患者实现更好的健康结果。</p>
</div><p><strong>About Kent Imaging</strong></p>
<div class="lb-trans"><p><strong>关于 Kent Imaging</strong></p>
</div><p>Based in Calgary, Alberta, Canada, Kent Imaging is a leading innovator in advanced diagnostic imaging technology. The company designs, manufactures, and markets medical devices that support real-time decision-making in wound care, vascular, and surgical specialties. Through patented technologies, Kent continues to deliver groundbreaking solutions that support healthcare systems around the world.</p>
<div class="lb-trans"><p>Kent Imaging 总部位于加拿大阿尔伯塔省卡尔加里，是先进诊断成像技术的领先创新者。该公司设计、制造和销售支持伤口护理、血管和外科专业实时决策的医疗设备。通过专利技术，Kent 不断提供突破性解决方案，支持全球医疗系统。</p>
</div><p>The Snapshot product suite now includes two powerful imaging devices: SnapshotNIR, a near-infrared tissue oxygenation imaging device initially cleared by the FDA and Health Canada in 2017 and CE-marked in 2025; and SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025. SnapshotNIR is supported by clinical evidence demonstrating its role in enhancing clinical decision-making, while SnapshotGLO provides real-time insight into wound bioburden presence and distribution. Together, the Snapshot product family strengthens clinicians' ability to detect, direct, and protect—promoting treatment consistency, supporting improved workflow, and contributing to better patient care worldwide.</p>
<div class="lb-trans"><p>Snapshot 产品系列现在包括两款强大的成像设备：SnapshotNIR，一种近红外组织氧合成像设备，最初于 2017 年获得 FDA 和加拿大卫生部的批准，并于 2025 年获得 CE 认证；以及 SnapshotGLO，一种细菌自发荧光成像设备，于 2025 年获得 FDA 510(k) 许可。SnapshotNIR 得到了临床证据的支持，证明其在增强临床决策中的作用，而 SnapshotGLO 则提供了对伤口生物负荷存在和分布的实时洞察。这些 Snapshot 产品系列共同增强了临床医生的检测、指导和保护能力，促进了治疗的一致性，支持了改善工作流程，并为全球更好的患者护理做出了贡献。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SnapshotGLO® is a registered trademark of Kent Imaging Inc.</td>
</tr>
<tr>
<td></td>
<td>SnapshotNIR® is a registered trademark of Kent Imaging Inc.</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SnapshotGLO® 是 Kent Imaging Inc. 的注册商标。</td>
</tr>
<tr>
<td></td>
<td>SnapshotNIR® 是 Kent Imaging Inc. 的注册商标。</td>
</tr>
</tbody>
</table>
</div><p>SOURCE Kent Imaging</p>
<div class="lb-trans"><p>来源 Kent Imaging</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE5Jk5ld3NJdGVtSWQ9Q0E2NTM3NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTkwODAwUFJfTkVXU19VU1BSX19fX19DQTY1Mzc2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CA65376&amp;Transmission_Id=202601190800PR_NEWS_USPR_____CA65376&amp;DateId=20260119"/></p>

Kent Imaging 对 ITC 关于 SnapshotGLO®的投诉作出回应，并重申其对临床创新的承诺